Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02810535
Other study ID # FRA.LISA.2015
Secondary ID
Status Completed
Phase N/A
First received May 31, 2016
Last updated November 29, 2017
Start date May 2016
Est. completion date September 19, 2017

Study information

Verified date November 2017
Source Johann Wolfgang Goethe University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to investigate the incidence of non-allergic rhinitis on a not selected group of young students (n=100-300). Students will be selected by public posting. In all students an allergy skin test will be performed. Then the local IgE of 24 subjects with non-allergic rhinitis will be compared to the local IgE of 24 subjects with allergic rhinitis and positive prick test to house dust mite. In addition 20 controlls will be investigated. Based on these investigations, the importance of local IgE and the IgE spectrum in conjunction with rhinitis should be further clarified.


Description:

20% of Germans suffer from seasonal or all-season rhinitis. Despite typical allergic symptoms, in a part of the affected patients (about 10-20%) an allergy cannot be found on skin prick test or blood. Therefore, the planned trial will investigate the incidence of allergic and non-allergic rhinitis in a non selected group of young students (n=100-300). The hypothesis postulates that in test subjects with non-allergic rhinitis the allergy can only be proven locally in nasal secretion.

From the initial large cohort of patients, 24 subjects with house dust mite allergy and allergic rhinitis and 24 patients with non-allergic rhinitis will be selected and investigated in more detail at a second visit. At the second visit, blood and nasal secretion (measurement of local IgE) will be taken from all pre-selected 48 patients. At visit 2 a nasal provocation test with house dust mite allergen will be performed in all patients to compare nasal symptoms with the results of local IgE between patient groups. In addition the same investigations will be performed in a group of 20 healthy non-allergic subjects.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date September 19, 2017
Est. primary completion date August 1, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Informed consent

- Seasonal or all-season symptoms of an allergic or non-allergic rhinitis

- Healthy non-allergic subjects

Exclusion Criteria:

- Patients: Age <18 and > 45

- Other severe diseases (e.g. Cystic fibrosis, diseases with immunosuppression, malignant diseases)

- Previously occurred allergic shock

- Pregnancy and lactation

- Participation in another clinical trial within the last 30 days

- Inability to measure the length and the consequences of the study

- Frequent use of medication which could not be discontinued in the defined time before enrollment: nasal vasoconstrictors 1 day; antihistamines 3 days; nasal steroids 7 days; oral cortison 4 weeks; leukotriene antagonists and cromolyn 2 days before NPT

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observation
Visit 1: Physical examination (inspection of nasopharynx, auscultation of heart and lungs) Completion of a Health Questionnaire Lung function testing with spirometry Skin prick test Visit 2: Physical examination (inspection of nasopharynx, auscultation of heart and lungs) Measurement of nitric oxide in expired air (FeNO) Taking nasal secretion samples with a cotton carrier for 15 min Nasal provocation test with dust mite Blood sample collection to define blood count, IgE and specific IgE

Locations

Country Name City State
Germany Goethe University Hospital Frankfurt Frankfurt am Main Hessen

Sponsors (1)

Lead Sponsor Collaborator
Johann Wolfgang Goethe University Hospital

Country where clinical trial is conducted

Germany, 

References & Publications (5)

Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, Kamin W, Berg AV, Wahu U, Zielen S. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2004 Jul;34(7):1079-85. — View Citation

Buslau A, Voss S, Herrmann E, Schubert R, Zielen S, Schulze J. Can we predict allergen-induced asthma in patients with allergic rhinitis? Clin Exp Allergy. 2014 Dec;44(12):1494-502. doi: 10.1111/cea.12427. — View Citation

Campo P, Rondón C, Gould HJ, Barrionuevo E, Gevaert P, Blanca M. Local IgE in non-allergic rhinitis. Clin Exp Allergy. 2015 May;45(5):872-881. doi: 10.1111/cea.12476. Review. — View Citation

Huggins KG, Brostoff J. Local production of specific IgE antibodies in allergic-rhinitis patients with negative skin tests. Lancet. 1975 Jul 26;2(7926):148-50. — View Citation

Litvyakova LI, Baraniuk JN. Nasal provocation testing: a review. Ann Allergy Asthma Immunol. 2001 Apr;86(4):355-64; quiz 364-5, 386. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of IgE between 24 subjects with non-allergic rhinitis, 24 subjects with allergic rhinitis and 20 healthy subjects. one year
Secondary Comparison of specific IgE between 24 subjects with non-allergic rhinitis, 24 subjects with allergic rhinitis and 20 healthy subjects. one year
Secondary Correlation between Peak Nasal Inspiratory Flow as well as the nasal symptoms in nasal provocation test and local specific IgE. one year
Secondary Explorative Measures: Comparison of the nasal and serum epitope spectrum with the new mite specific IgE component-chip in subjects with allergic rhinitis. one year
See also
  Status Clinical Trial Phase
Completed NCT01369563 - Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis N/A